Navigation Links
PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
Date:3/19/2009

ANNAPOLIS, Md., March 19 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2008 will be released on Monday, March 30, 2009.

PharmAthene management will be hosting a conference call to discuss its year end financial results. The call is scheduled to begin at 4:30 p.m. Eastern Time on Monday, March 30, 2009 and will last approximately 45 minutes.

The dial-in number within the United States is 866-383-8003. The dial-in number for international callers is 617-597-5330. The participant passcode is 25699583.

A replay of the conference call will be available for 30 days, beginning at approximately 7:30 p.m. Eastern Time on Monday, March 30, 2009 until approximately 11:59 p.m. Eastern Time on April 30, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 35301584.

The conference call will also be webcast and can be accessed from the company's website at www.pharmathene.com. A link to the webcast may be found on both under the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.

    Contact:
    Stacey Jurchison
    PharmAthene, Inc.
    Phone: 410-269-2610
    Stacey.Jurchison@PharmAthene.com


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2020)... ... January 07, 2020 , ... Vuja De Sciences (“Vuja De”), a biotechnology startup ... the appointments of Chand Khanna, DVM, PhD, DACVIM (Onc), and Dr. Lee Helman, MD, ... “We are delighted to welcome Chand and Lee as new directors. They will be ...
(Date:12/31/2019)... ... December 31, 2019 , ... ... pharmaceutical product development lab in Maryland. Emphasis will be in expanding ... expanded capabilities, Vici Health Sciences will be well positioned to meet the growing ...
(Date:12/27/2019)... ... December 27, 2019 , ... Vici Health ... 505(b)(2) product pipeline that offers patients and healthcare providers options in the ... identified in collaboration with doctors and managed care professionals and developed at Vici’s ...
(Date:12/18/2019)... ... December 18, 2019 , ... Tune in to CNBC ... by Ted Danson. Check local listings for more information on this program. , With ... reality are helping to simplify complex system to increase the efficiency, safety and effectiveness ...
Breaking Biology Technology:
(Date:12/31/2019)... ... December 31, 2019 , ... Chelonian Conservation ... but researchers struggle to gather even basic information about this shy, burrowing reptile. ... used to identify individual animals, allowing agencies to monitor this threatened, federally protected ...
(Date:12/18/2019)... ... December 17, 2019 , ... ... enrollment of first patients in its U.S. Phase 3 study VISTA-2 building on ... compound in patients with moderate to severe Dry Eye Disease (DED). SkQ1 belongs ...
(Date:12/14/2019)... ... December 11, 2019 , ... Fiberstar, ... food and beverage industry won the 2019 Food Ingredient Europe’s plant-based innovation award. ... rapidly growing plant-based foods category. Fiberstar who was one of three finalists achieved ...
Breaking Biology News(10 mins):